The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.
Sony S. Thazhath
◽
Chinmay S. Marathe
◽
Tongzhi Wu
◽
Jessica Chang
◽
Joan Khoo
◽
...
2014 ◽
Vol 16
(12)
◽
pp. 1257-1264
◽
J. Reusch
◽
M. W. Stewart
◽
C. M. Perkins
◽
D. T. Cirkel
◽
J. Ye
◽
...
Annemie Stege Bojer
◽
Martin Heyn Sørensen
◽
Jenny Bjerre
◽
Peter Gæde
◽
Niels Vejlstrup
◽
...
Lu Lin
◽
Xiangjin Xu
◽
Yunjie Yu
◽
Hongjiang Ye
◽
Xiaoqiong He
◽
...
2016 ◽
Vol 19
(2)
◽
pp. 200-207
◽
Michael A. Nauck
◽
Melanie Kahle
◽
Oleg Baranov
◽
Carolyn F. Deacon
◽
Jens J. Holst
2018 ◽
Vol 67
(Supplement 1)
◽
pp. 2231-PUB
SASAN FAZELI
◽
NICOLE EHRHARDT
2020 ◽
Vol 69
(Supplement 1)
◽
pp. 938-P
RALEIGH E. MALIK
◽
REEMA MODY
◽
MAUREEN J. LAGE
◽
KRISTINA BOYE
Thomas M. Caparrotta
◽
Jack B. Templeton
◽
Thomas A. Clay
◽
Sarah H. Wild
◽
Rebecca M. Reynolds
◽
...
2018 ◽
Vol 36
(2)
◽
pp. 138-147
◽
Vanita R. Aroda
◽
Joseph R. Arulandu
◽
Anthony J. Cannon
2018 ◽
Vol 39
(suppl_1)
◽
I Ikonomidis
◽
G Pavlidis
◽
V Lambadiari
◽
F Kousathana
◽
H Triantafyllidi
◽
...
Close
Export Citation Format
Close
Share Document
Close